Moreover, treatment options for patients with ALS and FTD are limited and although more than 60 different drugs covering multiple affected pathways have been tested in clinical trials, only two of them have been approved for clinical use by the FDA and EMA: riluzole for ALS [21-24] and QALSODY® (Tofersen) for the treatment of patients with ALS due to mutations in the SOD1 gene [21,24,25]. Here, SOD1 is linked to amyotrophic lateral sclerosis.